10.17.17
Johnson & Johnson today announced sales of $19.7 billion for the third quarter of 2017, an increase of 10.3% as compared to the third quarter of 2016. Operational sales results increased 9.5% and the positive impact of currency was 0.8%. Domestic sales increased 9.7% and international sales rose 10.9%, reflecting operational growth of 9.3% and a positive currency impact of 1.6%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide, domestic and international sales each increased 3.8%, according to the company.
Worldwide Consumer sales of $3.4 billion for the third quarter 2017 represented an increase of 2.9% versus the prior year, consisting of an operational increase of 1.6% and a positive impact from currency of 1.3%. Domestic sales decreased 0.5%, international sales increased 5.1%, which reflected an operational increase of 3.0% and a positive currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.1%, domestic sales decreased 0.7% and international sales increased 2.3%.
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by over-the-counter products primarily Tylenol analgesic products and international smoking cessation aids as well as OGX and Neutrogena beauty products, partially offset by the negative impact of domestic baby care products, according to J&J.
The company increased its sales guidance for the full-year 2017 to a range of $76.1 billion to $76.5 billion.
Worldwide Consumer sales of $3.4 billion for the third quarter 2017 represented an increase of 2.9% versus the prior year, consisting of an operational increase of 1.6% and a positive impact from currency of 1.3%. Domestic sales decreased 0.5%, international sales increased 5.1%, which reflected an operational increase of 3.0% and a positive currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.1%, domestic sales decreased 0.7% and international sales increased 2.3%.
Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by over-the-counter products primarily Tylenol analgesic products and international smoking cessation aids as well as OGX and Neutrogena beauty products, partially offset by the negative impact of domestic baby care products, according to J&J.
The company increased its sales guidance for the full-year 2017 to a range of $76.1 billion to $76.5 billion.
